Table 1.
Adverse events for STARPAC clinical trial.
| Adverse events (AE) summary | ||
|---|---|---|
| DL5 patients | All patients | |
| Total patients (N) | 19 | 27 |
| AEs reported, n | 470 | 638 |
| Patients with at least one AE, n | 19 | 27 |
| AEs per patienta, median (range) | 23 (8–71) | 23 (8–71) |
| ≥Grade 3 AEsa reported, n | 33 | 55 |
| Patients with at least one ≥Grade 3 AE, n | 11 | 17 |
| ≥Grade 3 AEs per patienta, median (range) | 3 (1–5) | 3 (1–9) |
Distribution of AE. AE ≥ grade 3 and DLTs in all patients and those receiving DL5 (RP2D) according to SOC term, whether attributable or not to treatment. N = number of patients in the Safety Set population for the specified group of patients.
aCounts of each instance, e.g., if one patient has the same term three times this is counted as three instances.